Dalcetrapib
| CAS No. | 211513-37-0 | Cat. No. | BCP01932 |
| Name | Dalcetrapib | ||
| Synonyms | JTT-705;RO-4607381;JTT705;JTT 705;RO 4607381;RO4607381; | ||
| Formula | C23H35NO2S | M. Wt | 389.59 |
| Description | Dalcetrapib modulates CETP activity. Dalcetrapib induces a conformational change in CETP, when added to human plasma. CETP-induced pre-β-HDL formation in human plasma is unchanged by Dalcetrapib ≤3 μM and increased at 10 μM. Dalcetrapib statistically and significantly increases pre-β-HDL formation.Dalcetrapib achieves 50% inhibition of CETP activity in human plasma at a concentration of 9 μM. [2] Dalcetrapib inhibits the CETP activity of media in HepG2 in a dose-dependent manner. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | CETP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.